IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.
about
Molecular pathological classification of colorectal cancerThe Insulin/IGF System in Colorectal Cancer Development and Resistance to TherapyDevelopment of a Whole Organism Platform for Phenotype-Based Analysis of IGF1R-PI3K-Akt-Tor Action.Lack of association between insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: a meta-analysis.IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma.Biomarker correlation network in colorectal carcinoma by tumor anatomic location.RETRACTED: Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected]Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic CholangiocarcinomamicroRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2.MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers.Polymorphisms of insulin receptor substrate 2 are putative biomarkers for pediatric medulloblastoma: considering the genetic susceptibility and pathological diagnoses.Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients.Overexpression of insulin receptor substrate-4 is correlated with clinical staging in colorectal cancer patients.IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma.Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma
P2860
Q26744251-17ED5949-C7C2-47C1-BF63-E28D55395529Q26777125-19C6E89A-9E6E-4557-A405-954EFCC4BE84Q30356087-66489F01-0FFE-452D-AADF-371C0A404428Q31150038-8953E7DF-6F55-41BB-B5FA-E3CA399D55AAQ33757043-5C531459-CF46-4066-A10D-B2F3690C6CB5Q33808553-92694C05-72EE-468D-BAC2-954E70E1C44BQ35097075-A5C9E752-31BE-40EA-8B54-263C0B45ED1DQ35346489-52B9F1D5-62F9-42AE-AA8B-EE1DD83BD7F7Q35873406-573F0B51-767A-4AC7-B6FD-79344C3512B6Q36878582-807E7B98-EBF8-4F64-A577-176CB04810DBQ37596819-19C3486E-C506-4C76-9992-A716D0ED2C22Q37610120-33E957BF-FC34-4093-A66F-658649CD06A2Q37694595-F70F360F-E8A8-43CB-81E1-3E5E4042E9CFQ39483070-8D27EA4B-246F-40AC-BFC6-AFD8593B6F83Q41978977-2A36B9E3-2F6F-4888-92CE-8732C9C2265FQ47594924-7F6DE5DF-E214-4F8E-90CC-9AE6CB51962BQ53407519-7A31D42E-9A20-4EF7-94A5-56C4D3BDC332Q58794872-BCCBD0CA-7048-4221-ABEB-354F07DB33F0
P2860
IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.
@en
type
label
IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.
@en
prefLabel
IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.
@en
P2093
P2860
P356
P1476
IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer
@en
P2093
Ashraf E K Ibrahim
Elizabeth Day
Frank McCaughan
Mark J Arends
Paul H Dear
Shani Mulholland
P2860
P304
P356
10.1111/IEP.12021
P577
2013-04-18T00:00:00Z